

Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure

George Markousis-Mavrogenis, Waldemar B Minich, Ali A Al-Mubarak, Stefan D Anker, John G F Cleland, Kenneth Dickstein, Chim Lang, Leong Ng, Nilesh J Samani, Faiez Zannad, et al.

▶ To cite this version:

George Markousis-Mavrogenis, Waldemar B
 Minich, Ali A Al-Mubarak, Stefan D Anker, John G
 F Cleland, et al.. Clinical and prognostic associations of autoantibodies recognizing adrener
gic/muscarinic receptors in patients with heart failure. Cardiovascular Research, 2023, 119 (8), pp.1690-1705.
 $10.1093/\rm cvr/\rm cvad042$. hal-04023791

HAL Id: hal-04023791 https://hal.univ-lorraine.fr/hal-04023791v1

Submitted on 10 Mar 2023 $\,$

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NoDerivatives 4.0 International License

Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure

3

1

2

George Markousis-Mavrogenis ^a, MD (Hons); Waldemar B. Minich ^{b,c}, MSc, PhD; Ali A. Al-Mubarak ^a, MD;
Stefan D. Anker ^{d,e}, MD, PhD; John G.F. Cleland ^f, MD, PhD; Kenneth Dickstein ^g, MD, PhD; Chim C. Lang ^h,
MD; Leong L. Ng ⁱ, MD; Nilesh J. Samani ⁱ, MD; Faiez Zannad ^j, MD, PhD, Marco Metra ^k, MD, PhD, Petra
Seemann ^{b,c}, MSc, PhD; Antonia Hoeg ^b, MSc, PhD; Patricio Lopez ^{b,c}, MSc, PhD; The BIOSTAT-CHF
Consortium; Dirk J. van Veldhuisen ^a, MD, PhD; Rudolf A. de Boer ^a, MD, PhD; Adriaan A. Voors ^a, MD, PhD;
Peter van der Meer ^a, MD, PhD; Lutz Schomburg*^{t b}, MSc, PhD; Nils Bomer* ^a, MSc, PhD.

- a. Department of Cardiology, University Medical Center Groningen, University of Groningen,
 Groningen, the Netherlands
- b. Institute for Experimental Endocrinology, Charité Universitätsmedizin Berlin, Hessische Straße
 4A, CCM, D-10115 Berlin, Germany
- 14 c. ImmunometriX GmbH i.L. Berlin, Germany
- d. Division of Cardiology and Metabolism Heart Failure, Cachexia & Sarcopenia; Department of
 Cardiology (CVK); and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), at Charité
 University Medicine, Berlin, Germany
- e. Department of Cardiology and Pneumology, University Medicine Göttingen (UMG), Göttingen,
 Germany & DZHK (German Center for Cardiovascular Research)
- f. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8TA;
 National Heart & Lung Institute, Imperial College London SW3 6LY. UK.
- 22 g. University of Bergen, Stavanger University Hospital, Stavanger, Norway
- 23 h. Division of Molecular & Clinical Medicine, University of Dundee, Dundee DD1 9SY, UK
- i. Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK
 and NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, LE3 9QP, UK
- 26 j. Université de Lorraine, Inserm CIC 1403, CHRU, Nancy, France
- k. Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological
 Sciences and Public Health, University of Brescia, Brescia, Italy
- 30 *These authors have contributed equally to the manuscript.
- 31 +Corresponding author
- 32

29

- 33 Short Title: Autoantibodies in Heart Failure
- 34 Keywords: beta 1, beta 2, beta 3, M2, immune system, autoimmunity
- 35

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<u>https://creativecommons.org/licenses/by/4.0/</u>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Address for correspondence: Prof. Lutz Schomburg, Charité – Universitätsmedizin Berlin, 10115 Berlin,
 Germany. Email address: lutz.schomburg@charite.de

3 Abstract

Aims. The importance of autoantibodies (AABs) against adrenergic/muscarinic receptors in heart failure
(HF) is not well-understood. We investigated the prevalence and clinical/prognostic associations of four
AABs recognizing the M2-muscarinic receptor or the β1-, β2-, or β3-adrenergic receptor in a large and wellcharacterized cohort of patients with HF.

Methods and Results. Serum samples from 2256 patients with HF from the BIOSTAT-CHF cohort and 8 9 299 healthy controls were analyzed using newly established chemiluminescence immunoassays. The primary outcome was a composite of all-cause mortality and HF-rehospitalization at 2-year follow-up, and 10 each outcome was also separately investigated. Collectively, 382 (16.9%) patients and 37 (12.4%) controls 11 were seropositive for ≥ 1 AAB (p=0.045). Seropositivity occurred more frequently only for anti-M2 AABs 12 (p=0.025). Amongst patients with HF, seropositivity was associated with the presence of comorbidities 13 14 (renal disease, chronic obstructive pulmonary disease, stroke, atrial fibrillation), and with medication use. Only anti-β1 AAB seropositivity was associated with the primary outcome [hazard ratio (95% confidence 15 interval): 1.37 (1.04-1.81), p=0.024] and HF-rehospitalization [1.57 (1.13-2.19), p=0.010] in univariable 16 analyses, but remained associated only with HF-rehospitalization after multivariable adjustment for the 17 BIOSTAT-CHF risk model [1.47 (1.05-2.07), p=0.030]. Principal component analyses showed considerable 18 overlap in B-lymphocyte activity between seropositive and seronegative patients, based on 31 circulating 19 biomarkers related to B-lymphocyte function. 20

Conclusions. AAB seropositivity was not strongly associated with adverse outcomes in HF and was mostly
 related to the presence of comorbidities and medication use. Only anti-β1 AABs were independently
 associated with HF-rehospitalization. The exact clinical value of AABs remains to be elucidated.w

1 Translational Perspective.

Currently, little is known regarding the clinical/prognostic associations of ANS-AABs in patients with HF.
We show that out of four investigated ANS-AABs, only anti-β1 AAB seropositivity was independently
associated with HF-rehospitalization. Seropositivity for any of the investigated AAB was not associated
with changes in circulating B-lymphocyte-related markers. Seropositivity was highly similar when
compared to healthy controls. These findings support a limited prognostic role for ANS-AABs in the general
HF population and suggest that ANS-AAB generation may be constitute a previous event unrelated to HF.
Future studies should investigate specific target groups such as Chagas cardiomyopathy, non-hereditary

9 DCM and PPCM.

10

11 Abbreviation list

ABBREVIATION	DEFINITION
HF	Heart failure
AAB	Autoantibody
ANS-AAB	Autoantibodies against autonomic nervous system receptors
DCM	Dilated cardiomyopathy
BIOSTAT-CHF	A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure
LVEF	Left ventricular ejection fraction
BNP	Brain natriuretic peptide
NT-PROBNP	N-terminal pro-brain natriuretic peptide
ACEI/ARB	Angiotensin converting enzyme inhibitor/angiotensin receptor blocker
BB	β-adrenoreceptor blocker
CRP	C-reactive protein
HS-CTNT	High-sensitivity cardiac troponin-T
EGFR	Estimated glomerular filtration rate
MDRD	Modification of Diet in Renal Disease
HR	Hazard ratio
95% CI	95% confidence interval
IL-6	Interleukin-6
ANOVA	Analysis of variance
PCA	Principal component analysis
COPD	Chronic obstructive pulmonary disease
AF	Atrial fibrillation
MRA	Mineralocorticoid receptor antagonist

PPCM

1

Peripartum cardiomyopathy

Downloaded from https://academic.oup.com/cardiovascres/advance-article/doi/10.1093/cvr/cvad042/7072338 by SCD NANCY I user on 10 March 2023

2 Introduction

Many studies have demonstrated the intricate relationship between immune activation and pathophysiological mechanisms in HF.¹ Nevertheless, direct immunomodulatory interventions have as of yet no established role in the clinical management of HF.

Antibodies are soluble forms of the B-cell receptor that are secreted by activated plasma cells and 6 7 constitute an important part of the adaptive immune response.² The generation of an effective immune response requires a broad antibody repertoire, which is achieved with impressive efficiency by 8 recombination of immunoglobulin genes.³ This permits the generation of antibodies with potentially infinite 9 specificities. Unavoidably, this process also leads to the generation of antibodies against self-antigens. 10 Specialized regulatory mechanisms have evolved to eliminate self-reactive lymphocytes⁴; nevertheless, 11 these do not always function optimally. Accordingly, self-reactive lymphocytes and autoantibodies (AABs) 12 feature prominently in numerous autoimmune rheumatic diseases ⁵ and other disease states.⁶ 13

A relationship between AABs against autonomic nervous system receptors (ANS-AABs) and HF has been described previously, particularly in patients with non-hereditary dilated cardiomyopathy (DCM)⁷ and Chagas cardiomyopathy.⁸ However, to our knowledge, most reports are limited to small cohorts and no data from large, well-characterized, and diverse populations currently exist in the literature. We thus aimed to investigate the prevalence of ANS-AAB seropositivity in patients with HF, and to determine its clinical associations and potential relationships with outcomes.

1 Methods

2 <u>Patients</u>

We performed a post-hoc analysis of the BIOSTAT-CHF index cohort (n=2516), which has been 3 described previously.⁹ Briefly, BIOSTAT-CHF was a multi-center study enrolling patients from 11 4 5 European countries. Participants were aged ≥ 18 years, had symptoms of new-onset or worsening HF, combined with a left ventricular ejection fraction (LVEF) $\leq 40\%$ or brain-type natriuretic peptide (BNP) 6 and/or N-terminal pro-BNP (NT-proBNP) plasma levels >400 pg/mL or >2,000 pg/mL, respectively. 7 Participants were either not previously treated with angiotensin converting enzyme inhibitors/angiotensin 8 receptor blockers (ACEi/ARB) and/or β -adrenoreceptor blockers (BB) or were receiving $\leq 50\%$ of guideline-9 10 recommended target doses and anticipated their initiation or up-titration. All patients were treated with loop diuretics. Participants could be enrolled as inpatients or outpatients. The primary outcome was a composite 11 12 of all-cause mortality and rehospitalization for HF censored at 2-year follow-up, with each component separately constituting a secondary outcome. The study protocol was approved by local and national ethics 13 committees (EudraCT 2010-020808-29; R&D Ref Number 2008-CA03; MREC Number 10/S1402/39) and 14 all participants provided written informed consent. The study was performed according to the principles 15 outlined in the Declaration of Helsinki. 16

17 <u>Autoantibody Measurements</u>

Measurements of autoantibody titers against β1-, β2- and β3-adrenergic receptors, as well as M2muscarinic receptors were performed using chemiluminescence immunoassays (ImmunometriX, Berlin,
Germany) on blood serum samples from 2256/2516 (89.7%) patients from the BIOSTAT-CHF index cohort,
and in 299 controls that self-identified as healthy [acquired commercially from in.vent Diagnostica (Berlin,
Germany)]. Assay development and calculation of binding indices are described in the Supplementary
Methods. For quality control of the anti-β1 AAB assay, one negative and one positive sample from the

control group (binding index below the median and higher than 10 respectively) was measured in duplicate 1 2 in all microtiter plates during analysis (n=26 duplicates each). As there is no prior knowledge on the threshold for relevant AABs concentrations, the 99th percentile value of negative controls (1.3883) was used 3 4 to define a cut-off under which an assay would be considered definitively negative (henceforth 5 "seronegative"), while the 1st percentile value of positive controls (7.3818) was similarly used to define a cut-off above which, an assay would be considered definitively positive (henceforth "seropositive") 6 7 (Supplementary Figure 1). Patients with assay results in-between the two cut-off values were labelled 8 "intermediate". The same cut-offs were also applied for defining subgroups in the remaining AAB assays.

9 <u>Laboratory Indices</u>

Estimated glomerular filtration rate (eGFR) was calculated using the modification of diet in renal
disease (MDRD) formula. NT-proBNP and hs-cTnT were measured using sandwich immunoassays (Roche
Inc.), and CRP was measured using competitive immunoassays on a Luminex platform (Alere Inc.). Anemia
was defined according to the World Health Organization definition.

14 <u>Biomarker Measurements</u>

Plasma biomarkers were determined using the proximity extension assay technology (Olink 15 proteomics Inc.), as part of four biomarker panels involving 92 biomarker measurements each 16 (Cardiovascular-II, Cardiovascular-III, Immune Response and Oncology II panels), thus 368 biomarkers in 17 total. The complete list of available biomarkers has been reported previously.¹⁰ Overlapping biomarkers 18 between the four panels were amphiregulin, c-kit ligand and tissue factor pathway inhibitor-2 (measured 19 20 twice), as well as interleukin-6 (IL-6) (measured three times). For overlapping biomarkers, the mean of all measurements was used, leaving a total of 363 unique biomarkers. Additionally, eight biomarkers were 21 22 excluded from analyses because >10% of measurements were outside the assay's limit of detection. Thus, 23 in total, 355 biomarkers were available for further analysis.

CVR-2022-1307

1 <u>Pathway Over-representation Analysis</u>

Pathway over-representation analysis of the 355 biomarkers was performed using the "GProfiler" 2 pathway analyzer (version e104 eg51 p15 3922dba).¹¹ The results of the analysis were classified based on 3 4 the gene ontology classification of biological processes (annotation 2022-01-13).¹² Corrections for multiple testing were performed using the built-in g:SCS algorithm, using a false discovery rate threshold of 5%. 5 Only significantly over-represented processes that included ≥ 5 of their constituents, were included in the 6 final selection. The biomarker corneodesmosin could not be analyzed by GProfiler, and since the biomarkers 7 8 BNP and NT-proBNP share the same protein designation, the effective number of analyzed biomarkers was 9 eventually 353.

10 Selection of GO Biological Processes Related to B-lymphocytes and Antibodies

11 The pathway over-representation analysis of the 353 biomarkers yielded 768 over-represented 12 biological processes. Of these, 13 contained the terms "B cell" and "immunoglobulin". To eliminate 13 potential data redundancies due to member overlap between processes¹⁰, the 13 selected processes were 14 visualized in a directed acyclic graph, and the most distal non-redundant processes were selected (**Figure** 15 **1A, Figure 1B, Supplementary Figure 2**). This yielded five processes related to B-lymphocytes and 16 antibodies, represented by different combinations of 31 biomarkers (**Figure 1C**).

17 <u>Statistical Analysis</u>

18 Statistical analyses were conducted using R-studio (R version 4.2.0). Normality of continuous 19 variables was determined by visual inspection of histograms and Q-Q plots. Baseline characteristics were 20 compared for each of the four investigated AABs between seronegative, intermediate, and seropositive 21 patients. Normally distributed variables were compared using one-way analyses of variance (ANOVA), not-22 normally distributed continuous variables using Kruskal-Wallis tests, and categorical/binary variables using 23 Chi-square tests. In case of a significant ANOVA result, pairwise post-hoc testing with independent t-tests

1 using Bonferroni correction was performed. Chemiluminescence assay results for each AAB were compared 2 between patients with HF and healthy controls when considering the corresponding binding index as 3 continuous variable using the Mann-Whitney U test, and when classified based on the previously defined 4 groups by using Chi-square tests. Associations between autoantibody status and the primary outcome and 5 all-cause mortality were investigated using Kaplan-Meier curves, while associations with hospitalization 6 were investigated using cumulative incidence function curves while considering all-cause mortality a 7 competing risk. Univariable associations were investigated with log-rank tests, while multivariable corrections for previously published risk models for this cohort ⁹ were performed using Cox regression, 8 when statistical assumptions were met. These included, among others, age, comorbidities, measures of 9 congestion, NT-proBNP, and renal function⁹. Statistical testing in survival analyses was performed using 10 the log-rank test. Statistical significance was considered as $p \le 0.05$, considering the exploratory character of 11 12 this study.

Significant findings from survival analyses were further verified with propensity-score matching (MatchIt package v. 4.5.0) based on the aforementioned variables of BIOSTAT-CHF risk model. Seropositive patients were matched 1:1 to seronegative patients. A nearest-neighbor matching algorithm with a caliper of 0.2 and without replacement, taking into account the region of common support, was used for this purpose.¹³ Unmatched observations were discarded. Statistical as well as graphical balance diagnostics tools were performed in order to evaluate the matching process.

19 To investigate the relative state of B-lymphocyte function in seronegative and seropositive patients, 20 principal component analyses (PCA) were conducted for each AAB, by excluding patients that were 21 categorized as intermediate. Subsequently, the results were plotted on biplots with concentration ellipses for 22 each group.

1 Results

2	Baseline characteristics for the entire cohort are presented in Table 1. Mean age was 69 (12) years,
3	and 602 (26.7%) were women. Ischemia was the most prevalent primary etiology of HF (46%) and median
4	NT-proBNP was 2721.0 pg/mL [1204.3, 5741.8]. Median LVEF was 30% [25-37] and 216 (10.7%) patients
5	had an LVEF>40%. Healthy controls had a median age of 32 years [24, 40] (range: 18-63 years) and 134
6	(44.8%) were women.
7	Comparison of Assay Binding Indices in Healthy Controls and Patients with Heart Failure
8	Assay binding indices for each AAB are presented as continuous variables using half-violin plots
9	with superimposed boxplots and individual data points in Figure 2A. There were no statistically significant
10	differences between healthy controls and patients with HF in median binding index for anti- β 1 AABs [1.22]
11	(1.00, 1.59) vs. 1.23 (1.01, 1.73), p=0.238], anti-β2 AABs [1.24 (0.97, 2.01) vs. 1.25 (1.01, 1.88), p=0.516]
12	and anti-M2 AABs [1.32 (1.05, 2.02) vs. 1.31 (1.00, 2.25), p=0.722]. Patients with HF had a higher median
13	binding index for anti-β3 AABs [1.10 (0.89, 1.39) vs. 1.19 (1.01, 1.46), p<0.001].
14	Classification of Autoantibody Status
15	The relative prevalence of seronegative, intermediate, and seropositive status amongst healthy
16	controls and patients with HF are presented in Figure 2B. The prevalence of seropositivity amongst patients
17	with HF in increasing order was 1.8% (n=41) for anti- β 3, 5.1% (n=114) for anti- β 1, 5.9% (n=133) for anti-
18	β 2, and 7.6% (n=172) for anti-M2 AABs. The proportion of groups was significantly different between
19	patients with HF compared with healthy controls only for anti-M2 AABs, driven by a higher proportion of

seropositive patients (p=0.025). In total, 382 (16.9%) patients with HF were classified as seropositive for at
least one AAB, compared with 37 (12.4%) of the healthy controls (p=0.045). Summary statistics for assay
binding indices in total and stratified by AAB status are presented in Supplementary Tables 1 and 2,
respectively.

1 The co-occurrence of either intermediate or seropositive status between the different AABs is 2 presented in **Figure 2C**, while the co-occurrence of seropositive status only is presented in **Figure 2D**. 3 Among the 382 patients that were seropositive for at least one AABs, co-occurrence of seropositivity for 4 any of the remaining AABs had a low prevalence, with the highest value being observed for seropositivity 5 for all four AABs in 15/382 (3.9%) patients. Collectively, 340/382 (89.0%) patients were seropositive for 6 only one of the studied AABs.

7 <u>Clinical Associations of Autoantibody Seropositivity</u>

8 Baseline characteristics stratified by seronegative, intermediate, and seropositive groupings for each
9 AAB are presented in Tables 1-4 for anti-β1, anti-β2, anti-β3, and anti-M2 AABs, respectively.

10 Anti-β1-Autoantibodies

Anti-β1 AAB seropositivity was associated with a lower prevalence of a primary cardiomyopathy 11 etiology [seronegative vs. intermediate vs. seropositive: 372 (27.1%) vs. 169 (23.2%) vs. 15 (13.4%), 12 p=0.002], a higher prevalence of a history of renal disease [366 (26.2%) vs. 216 (29.1%) vs. 46 (40.1%), 13 p=0.004], anemia [446 (35.1%) vs. 250 (37.0%) vs. 50 (47.2%), p=0.043], and chronic obstructive 14 pulmonary disease (COPD) [232 (16.6%) vs. 133 (17.9%) vs. 30 (26.3%), p=0.030]. These were also 15 16 mirrored by corresponding changes in serum creatinine and hemoglobin (p=0.027 and 0.047 respectively). Lastly, seropositivity was associated with a lower prevalence of mineralocorticoid receptor antagonist 17 (MRA) use [766 (54.8%) vs. 379 (51.0%) vs. 51 (44.7%), p=0.045]. Amongst patients with a primary 18 ischemic HF etiology, β 1-seropositivity did not differ significantly amongst those with and without a history 19 of MI [40 (5.2%) vs. 17 (7.0%), p=0.514]. 20

1 Anti-β2-Autoantibodies

Anti-β2 AAB seropositivity was associated with history of stroke [129 (9.7%) vs. 63 (7.9%) vs. 20 2 3 (15.0%), p=0.027], and current smoking (p=0.021). The proportion of seropositive patients with an 4 LVEF ≥ 40% was modestly lower compared to seronegative patients [145 (12.2%) vs. 60 (8.5%) vs. 11 5 (9.2%), p=0.034]. Seropositive patients were more likely to have been recruited as outpatients rather than 6 inpatients [458 (34.6%) vs. 223 (28.0%) vs. 53 (39.8%), p=0.001]. Similar to anti-\beta1 seropositive patients, anti- β 2 seropositivity was associated with a lower prevalence of MRA use [677 (51.4) vs. 458 (57.5%) vs. 7 8 61 (45.9%), p=0.004]. Seropositive diabetics were also less likely to be using oral hypoglycemic agents 9 (p=0.042).

10 Anti- β 3-Autoantibodies

Anti-β3 AAB seropositivity was associated with a higher prevalence of atrial fibrillation (AF) and
COPD [687 (43.7%) vs. 316 (49.4%) vs. 21 (51.2%), p=0.038, and 260 (16.5%) vs. 123 (19.2%) vs. 12
(29.3%), p=0.044, respectively]. In addition, mean eGFR was lower in seropositive patients [65.92 (26.57)
vs. 62.98 (24.91) vs. 60.50 (31.33), p=0.032], with corresponding increases in serum creatinine (p=0.027).
Lastly, a greater proportion of seropositive patients was at the guideline-recommended target dose for BB
[84 (5.3%) vs. 36 (5.6%) vs. 7 (17.1%), p=0.006].

17 Anti-M2-Autoantibodies

Seropositivity for anti-M2 AABs was associated with a higher probability of being at the guidelinerecommended target dose for ACEi [157 (13.0%) vs. 105 (12.1%) vs. 33 (19.2%), p=0.040], as well as
higher probability of MRA use [615 (50.8%) vs. 477 (54.8%) vs. 104 (60.5%), p=0.026].

1 <u>Survival Analysis</u>

2 Kaplan-Meier survival curves are presented for each AAB in Figure 3A for the combined outcome, and all-cause mortality alone (Figure 3B) at 2-year follow-up. Cumulative incidence function curves for 3 4 the competing risk analysis of HF rehospitalization at 2-year follow-up with all-cause mortality as a 5 competing risk are presented in Figure 3C. Regarding the primary outcome, anti-\beta1 seropositive patients 6 trended towards a poorer prognosis, without reaching statistical significance (p=0.068). Anti- β 3 status was associated with the primary outcome, with seropositive patients having an overall better prognosis 7 (p=0.016). Anti-B2 and anti-M2 status were not significantly associated with the primary outcome. There 8 were no significant associations between AAB status and all-cause mortality. Competing risks analysis 9 revealed only a significant association between anti-ß1 seropositivity and a higher probability of HF 10 rehospitalization (p=0.029). A sensitivity analysis was performed after merging seronegative and 11 12 intermediate patients because these groups showed comparable results in previous survival analyses. This revealed that the primary outcome and HF rehospitalization alone were more frequent only in patients who 13 were seropositive for anti- β 1 AABs (p=0.023 and 0.008, respectively) (Figure 4). 14

Since the two significant comparisons for anti-\beta1 AABs in the sensitivity analysis also met the 15 criteria for the proportionality of hazards assumption, additional multivariable analyses were performed 16 17 (Cox regression for the combined outcome and competing risks regression for rehospitalization). Compared with seronegative/intermediate status, anti-ß1 seropositivity was associated with the combined outcome 18 [hazard ratio (HR), 95% confidence interval (95% CI): 1.37 (1.04-1.81), p=0.024] but ceased to be 19 20 significant when corrected for the previously published BIOSTAT-CHF risk model [HR (95% CI): 1.27 21 (0.97-1.68), p=0.087]. Anti- β 1 seropositivity was associated with HF rehospitalization both in univariable 22 analysis [HR (95%CI): 1.57 (1.13-2.19), p=0.010], and when adjusted for the BIOSTAT-CHF risk model 23 [HR (95% CI): 1.47 (1.05-2.07), p=0.030]. Additional validation was performed by means of propensity score matching as described in the methods section. All patients that were anti- β 1 seropositive except one 24

(n=113), were matched 1:1 to seronegative patients, forming well-balanced groups (standardized mean
differences <0.1, variance ratios <2). Seropositive patients had significantly higher risk for HF-
rehospitalization at 2-year follow-up (standardized HR (95% CI) 1.83 (1.08-3.10), p=0.024).

4 Because patients with intermediate AAB status seemed to have a different prognosis, particularly 5 in the case of anti- β 3 AABs (**Figure 3**), additional analyses were performed in patients with intermediate AAB status for all AABs, in order to investigate whether the AAB titer as a continuous variable was 6 associated with any of the examined outcomes (Supplementary Table 3). Intermediate patients for anti-B3 7 8 AABs showed an inverse association between anti- β 3 AAB titer and the combined outcome [HR (95% CI): 0.82 (0.71-0.94) for each 1-unit increase, p=0.006], which remained significant after adjustment for the 9 corresponding risk model [HR (95% CI): 0.83 (0.72-0.95), p=0.009]. In patients with intermediate anti-β2 10 status, AAB titers were associated with reduced all-cause mortality [HR (95% CI): 0.83 (0.72-0.95), 11 p=0.008]. However, this was no longer significant after multivariable correction for the corresponding risk 12 model (p=0.196). Patients with intermediate status for anti- β 1/anti-M2 AABs did not show associations 13 between their corresponding AAB titers and any examined outcomes. 14

15 Analysis of Circulating B-lymphocyte-Associated Markers in Relation to Autoantibody Seropositivity

PCA was used on the 31 B-lymphocyte-related biomarkers (**Figure 5**). Concentration ellipses were plotted for seropositive and seronegative individuals per AAB. All sub-analyses demonstrated considerable overlap between seropositive and seronegative patients. The relative contribution of the 31 biomarkers to the 1st and 2nd principal components is presented in **Supplementary Figure 3**.

In this post-hoc analysis of a large and heterogeneous cohort of patients with HF, 16.9% of patients were seropositive for at least one ANS-AAB. Overall, the prevalence of seropositivity did not significantly differ from that of healthy controls, with the exception of a significantly higher prevalence of seropositivity

²⁰ Discussion

for anti-M2 AABs. Seropositivity for ANS-AABs was associated with the presence of comorbidities (renal
 disease, COPD, AF, stroke), or ARB/MRA use. Only seropositivity for anti-β1 AABs was significantly
 associated with a higher probability of HF rehospitalization at 2-year follow-up. PCA revealed considerable
 overlap of B-lymphocyte activity between seropositive and seronegative patients with HF, based on 31
 circulating biomarkers.

6 Most studies evaluating ANS-AABs in patients with HF have been conducted in patients with Chagas cardiomyopathy and non-hereditary DCM, mostly focusing on anti-β1 and anti-M2 AABs. 7 8 Approximately a third of patients with asymptomatic Chagas disease have detectable anti- β 1, anti- β 2 and anti-M2 AABs, while almost all who develop cardiomyopathy, are seropositive for all aforementioned 9 AABs.⁸ Among patients with non-hereditary DCM, anti-\beta1 and anti-M2 AABs were detected in 31% and 10 36-39% of patients, respectively.¹⁴ Interestingly, immunoglobulin subclasses may also be relevant, as in 11 12 patients with DCM the presence of IgG3-anti-β1 AABs was associated with a better LVEF during followup compared with seronegative patients, or those with non-IgG3-anti-β1 AABs.¹⁵ Furthermore, an increased 13 prevalence of ANS-AAB seropositivity has been reported in women with peripartum cardiomyopathy 14 (PPCM) compared with healthy pregnant controls.¹⁶ In patients with non-hereditary DCM, anti-β1 AABs 15 16 are also associated with an increased risk of ventricular tachycardia and sudden cardiac death¹⁷, while anti-M2 AABs predict rehospitalization but not all-cause mortality in PPCM.¹⁸ In our study, we only identified 17 an independent association between seropositivity for anti- β 1 AABs with HF rehospitalization at 2-year 18 follow-up, similar to a previous study in a smaller cohort.¹⁹ This might be explained by counterbalance of 19 anti- β 1 AAB actions by anti- β 2 AABs,²⁰ although their co-occurrence was limited. Conversely, 20 21 seropositivity for anti-β3 AABs trended towards an association with better prognosis. However, the low seroprevalence of anti-\beta3 AABs made additional analyses difficult. 22

ANS-AABs can potentially influence cardiac function by causing inappropriate positive or negative
 chronotropic or inotropic effects, by inducing cardiomyocyte apoptosis, or by activating the complement

cascade.^{14,21-23} Other authors reported that anti-β1 AABs from patients with DCM enhanced T-cell 1 proliferation via PKA/MAPK-signaling, which was prevented by metoprolol.²⁴ They also reduced 2 interferon- γ production, while increasing IL-4 production by T-cells.²⁴ Anti- β 1 AABs also impaired 3 endothelial function in In Wistar rats by negatively affecting NO signaling.²⁵ In contrast, anti-B3 AABs from 4 patients with HF protected rats with abdominal aortic banding from developing LV dysfunction and 5 dilation.²⁶ Anti-β1 and anti-M2 AABs have been found to induce HF in rodents, which could be reversed 6 upon their removal.^{27,28} This suggests a drug-like function on their corresponding target receptors.²⁸ 7 However, the pharmacology governing these interactions is as of yet unclear²⁸ and the agonist or antagonist 8 characteristics of anti-\beta1 AABs can also be of interest with regard to whether their removal would lead to 9 clinical benefit.27 10

Extensive studies in the setting of autoimmunity have led to the identification of numerous 11 12 mechanisms underlying the generation of AABs. One such mechanism has been termed "molecular mimicry", which describes the process of antibody generation against microbial proteins, which are also 13 structurally homologous to self-peptides.²⁹ A search of the literature did not reveal the presence of any 14 structural homologues of ANS receptors; still, structural similarities between microbial peptides and ANS 15 16 receptors cannot be ruled out. A different mechanism involves the generation of AABs against strictly 17 intracellular antigens, as often occurs in autoimmune diseases (e.g. anti-nuclear antibodies, anti-cytoplasmic antibodies. etc.).³⁰ The latter is less likely in this case, considering that ANS receptors are transported to the 18 cell membrane. An additional explanation could be that B-lymphocytes expressing B-cell receptors that 19 20 recognize self-antigens with high affinity are efficiently depleted or functionally silenced, while Blymphocytes with medium- or low-affinity receptors may escape tolerance mechanisms and give rise to 21 antibody-producing plasma cells.³¹ Collectively, circulating markers of B-lymphocyte function did not 22 23 differ significantly between seropositive and seronegative patients in our PCA analyses, suggesting that 24 ANS-AAB generation was not an acute process.

Autoreactive B-lymphocytes and plasma cells also occur in the general population and 1 2 seropositivity for AABs associated with thyroid disorders or autoimmune diseases does not per se lead to 3 clinical manifestations.^{14,32,33} Yet, both within the field of cardiovascular disease, as well as in other disease 4 states, circulating ANS-AABs have been implicated in the pathophysiology of various diseases. The reasons 5 behind the differential effects of circulating AABs in the general population and in specific disease processes remain unknown. Natural autoreactive immunoglobulin-M (IgM) antibodies may protect from autoimmune 6 disease³⁴, while the subtype of circulating IgG antibodies as well as the glycosylation and sialylation status 7 of their Fc-segments regulate higher affinity binding to inhibitory Fcy receptors (FcyRIIA, FcyRIIB).³¹ 8 Interestingly, animal studies have shown that the generation of IgG antibodies with pro-inflammatory 9 profiles requires a T-lymphocyte-dependent immune response³⁵, which is in agreement with previous 10 findings by our group underlying the important prognostic role of T-lymphocyte activation in HF.¹⁰ 11 Furthermore, anti-\beta1 AABs from patients with HF lead to cardiac fibrosis, cardiomyocyte apoptosis, LV 12 dilatation, and increases in LV mass in wild-type mice, which was not observed in mice lacking T-13 lymphocytes.³⁶ The same study showed that blockade of IL-6 production using small interfering RNA in 14 wild-type mice ameliorated cardiomyocyte apoptosis, and that anti- β 1 AABs upregulated IL-6 production 15 in T-lymphocytes from patients with HF.³⁶ These findings illustrate the interplay between T-lymphocytes 16 and ANS-AABs and are further supported by the prognostic value of IL-6 in HF.37 17

18 Limitations

19 The post-hoc character of this study and the relatively low prevalence of AAB seropositivity suggest 20 that some analyses may have been underpowered, particularly in the case of anti- β 3 AABs. Additional 21 characteristics for the healthy control population were not available and could thus not be accounted for in 22 statistical analyses. Additionally, the control population was significantly different from the examined 23 patients (younger, more women) and our findings could suggest potential age-dependency of AAB 24 formation. Extensive antibody repertoire mapping was not performed, which might have led to the identification of AABs with greater prognostic implications. In addition, our study did not include any
patients with Chagas cardiomyopathy or PPCM and lacked the necessary data to determine the presence of
non-hereditary DCM. The BIOSTAT-CHF cohort included patients that were suboptimally treated for HF
and might thus not be representative of the general HF population. Furthermore, it could be hypothesized
that the uptitration of HF treatments after initial blood sampling could have masked or attenuated the effects
of AABs on outcomes. Lastly, we did not evaluate the functional characteristics of measured AABs (e.g.,
inhibitory, stimulatory) and the specific isotype/class, subclass and allotype of AABs were not determined.

8 Conclusion

In a large and heterogeneous population of patients with HF, seropositivity for ANS-AABs was not
 strongly associated with adverse outcomes and was mostly related to existing comorbidities and medication
 use, while only seropositivity for anti-β1 AABs was independently associated with rehospitalization for HF.
 Further studies are necessary to better elucidate the potential prognostic significance and clinical
 associations of ANS-AABs in patients with non-hereditary DCM, Chagas cardiomyopathy or PPCM.

14

15 Acknowledgements: No acknowledgements to disclose.

Funding: BIOSTAT-CHF was funded by the European Commission [FP7-242209-BIOSTAT-CHF;
EudraCT 2010-020808-29]. The analytical work was supported by the German Federal Ministry for
Economic Affairs and Energy (BMWi) and the European Social Fund (ESF); EXIST-Project "BridgeART", FKZ: 03EFLBE114.

Statement of contribution: GMM (design, analysis, interpretation, drafting, revision), WBM (analysis,
revision), AAaM (design, analysis, interpretation, revision), SDA (acquisition, revision), JGFC (acquisition,
revision), KD (acquisition, revision), CCL (acquisition, revision), LLN (acquisition, revision), NJS

 (acquisition, revision), FZ (acquisition, revision), MM (acquisition, revision), PS (design, acquisition, analysis, revision), AH (design, acquisition, analysis, revision), PL (design, acquisition, analysis, revision),
 DJvV (acquisition, revision), RAdB (acquisition, revision), AAV (acquisition, revision), PvdM (acquisition, revision), LS (conception, design, analysis, interpretation, revision), NB (conception, acquisition, analysis, interpretation, revision)

6 Disclosures: AAV received consultancy fees and/or research grants from AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cytokinetics, Merck, NovoNordisk, Novartis, and Roche diagnostics. PvdM received 7 consultancy fees and/or grants from Novartis, Corvidia, Singulex, Servier, Vifor Pharma, Astra Zeneca, 8 9 Pfizer and Ionis. R.A.d.B. received grants from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals Gmbh, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche and speaker fees from 10 Abbott, AstraZeneca, Bayer, Novartis, and Roche. F.Z. received personal fees for trial oversight 11 12 committees, advisory boards, or speakers' bureau from Acceleron, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer, Cardior, Cereno Scientific, Cellprothera, CVRx, G3 Pharmaceuticals, 13 Merck, Merck AG, Novartis, NovoNordisk, Pfizer, Servier, Vifor Fresenius, and is Co-Founder of 14 CardioRenal, CVCT. JGFC received consultancy fees and/or research grants from Abbott, Amgen, Astra-15 16 Zeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Cytokinetics, Idorsia, Johnson & Johnson, 17 Medtronic, Myokardia, Novartis, NI Medical, Pharmacosmos, Pharma Nord, Philips, Respicardia, Servier, Torrent, Vifor, Viscardia. M.M. reports fees from Actelion, Amgen, Astra-Zeneca, Livanova, Servier, Vifor 18 19 pharma and WindTree Therapeutics as member of clinical trials committees or advisory boards and from 20 Abbott vascular, Bayer, Boheringer Ingelhelm and Edwards Therapeutics for speeches at sponsored 21 meetings in the last three years. W.B.M., P.S. and P.L. are founders of ImmunometriX. W.B.M. and L.S. 22 are listed as inventors on a patent application. All other authors have no relationships to disclose that could 23 be construed as a conflict of interest with regard to this manuscript.

1 References

2	1.	Linthout S Van, Tschöpe C. Inflammation - Cause or Consequence of Heart Failure or Both? Curr Heart
3		<i>Fail Rep</i> Curr Heart Fail Rep; 2017; 14 :251–265.
4	2.	Shapiro-Shelef M, Calame KC. Regulation of plasma-cell development. Nat Rev Immunol Nature Publishing
5		Group; 2005; 5 :230–242.
6	3.	Schatz DG, Ji Y. Recombination centres and the orchestration of V(D)J recombination. Nat Rev Immunol
7		Nature Publishing Group; 2011; 11 :251–263.
8	4.	Basten A, Silveira PA. B-cell tolerance: Mechanisms and implications. Curr Opin Immunol Elsevier Current
9		Trends; 2010; 22 :566–574.
10	5.	Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME. Definition of human autoimmunity - autoantibodies
11		versus autoimmune disease. Autoimmun Rev Elsevier; 2010;9:A259–A266.
12	6.	Siloși I, Siloși CA, Boldeanu MV, Cojocaru M, Biciușcă V, Avrămescu CS, Cojocaru IM, Bogdan M,
13		Folcuți RM. The role of autoantibodies in health and disease. Rom J Morphol Embryol Editura Academiei
14		Romane; 2016; 57 :633–638.
15	7.	Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, Lohse MJ. Direct evidence for a β 1-adrenergic
16		receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest
17		American Society for Clinical Investigation; 2004;113:1419–1429.
18	8.	Wallukat G, Muñoz Saravia SG, Haberland A, Bartel S, Araujo R, Valda G, Duchen D, Diaz Ramirez I,
19		Borges AC, Schimke I. Distinct Patterns of Autoantibodies Against G-Protein-Coupled Receptors in Chagas'
20		Cardiomyopathy and Megacolon. Their Potential Impact for Early Risk Assessment in Asymptomatic
21		Chagas' Patients. J Am Coll Cardiol J Am Coll Cardiol; 2010;55:463–468.
22	9.	Voors AA, Ouwerkerk W, Zannad F, Veldhuisen DJ van, Samani NJ, Ponikowski P, Ng LL, Metra M,
23		Maaten JM ter, Lang CC, Hillege HL, Harst P van der, Filippatos G, Dickstein K, Cleland JG, Anker SD,

24

16.

1		Zwinderman AH. Development and validation of multivariable models to predict mortality and
2		hospitalization in patients with heart failure. Eur J Heart Fail Eur J Heart Fail; 2017;19:627–634.
3	10.	Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, Ferreira JP, Anker SD, Cleland JG, Dickstein K,
4		Filippatos G, Lang CC, Metra M, Samani NJ, Boer RA de, Veldhuisen DJ van, Voors AA, Meer P van der.
5		Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from
6		BIOSTAT-CHF. Cardiovasc Res Cardiovasc Res; 2021;
7	11.	Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, Vilo J. g:Profiler: A web server for
8		functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res Oxford
9		Academic; 2019; 47 :W191–W198.
10	12.	Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS,
11		Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald
12		M, Rubin GM, Sherlock G. Gene ontology: Tool for the unification of biology. Nat. Genet. NIH Public
13		Access; 2000. p. 25–29.
14	13.	Zhao Q-Y, Luo J-C, Su Y, Zhang Y-J, Tu G-W, Luo Z. Propensity score matching with R: conventional
15		methods and new features. Ann Transl Med AME Publications; 2021;9:812–812.
16	14.	Kaya Z, Leib C, Katus HA. Autoantibodies in heart failure and cardiac dysfunction. Circ Res Lippincott
17		Williams & Wilkins Hagerstown, MD; 2012;110:145–158.
18	15.	Nagatomo Y, McNamara DM, Alexis JD, Cooper LT, Dec GW, Pauly DF, Sheppard R, Starling RC, Tang
19	(WHW, Janosko K, McTiernan C, London B, Hanley-Yanez K, Gorcsan J, Tanaka H, Suffoletto M, Oblak C,
20		McNallan A, Koenig LA, Mather P, Pierson N, Rubin S, Bell Y, Ervin A, Boehmer J, Frey P, Alexis J,
21		Schrack J, LaDuke P, Torre-Amione G, et al. Myocardial Recovery in Patients With Systolic Heart Failure
22		and Autoantibodies Against β1-Adrenergic Receptors. J Am Coll Cardiol J Am Coll Cardiol; 2017;69:968–
23		977.

Liu J, Wang Y, Chen M, Zhao W, Wang X, Wang H, Zhang Z, Zhang J, Xu L, Chen J, Yang X, Zhang L.

1

2		PLoS One PLoS One; 2014;9.
3	17.	Iwata M, Yoshikawa T, Baba A, Anzai T, Mitamura H, Ogawa S. Autoantibodies against the second
4		extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients
5		with idiopathic dilated cardiomyopathy. J Am Coll Cardiol American College of Cardiology
6		FoundationWashington, D.C.; 2001; 37 :418–424.
7	18.	Ma G, Wang Y, Hou D, Liu J, Zhang J, Xu L, Wang H, Zhao W, Zhang Y, Zhang L. Association of
8		autoantibodies against the M2-muscarinic receptor with long-term outcomes in peripartum cardiomyopathy
9		patients: A 5-year prospective study. J Cardiol Elsevier; 2019;74:251–257.
10	19.	Nagatomo Y, Li D, Kirsop J, Borowski A, Thakur A, Tang WHW. Autoantibodies Specifically Against $\beta 1$
11		Adrenergic Receptors and Adverse Clinical Outcome in Patients With Chronic Systolic Heart Failure in the
12		β-Blocker Era: The Importance of Immunoglobulin G3 Subclass. J Card Fail NIH Public Access;
13		2016; 22 :417–422.
14	20.	Cao N, Chen H, Bai Y, Yang X, Xu W, Hao W, Zhou Y, Chai J, Wu Y, Wang Z, Yin X, Wang L, Wang W,
15		Liu H, Fu MLX. β 2-adrenergic receptor autoantibodies alleviated myocardial damage induced by β 1-
16		adrenergic receptor autoantibodies in heart failure. Cardiovasc Res Oxford Academic; 2018;114:1487–1498.
17	21.	Zhang Y, Liu J, Shi L, Chen M, Liu J. β 1-Adrenoceptor antibodies induce PPCM via inhibition of PGC-1 α
18		related pathway. Scand Cardiovasc J Taylor and Francis Ltd.; 2021;55:160–167.
10	22	Charlet A. Mahini D. E. M. Carles V. Changl V. Changl V. Thiele A. Deumonn C. Eslin CD. 81 advancementary
19	22.	Staudt A, Mobini R, Fu M, Große Y, Stangl V, Stangl K, Thiele A, Baumann G, Felix SB. β1-adrenoceptor
20		antibodies induce positive inotropic response in isolated cardiomyocytes. Eur J Pharmacol Eur J Pharmacol;
21	Y	2001; 423 :115–119.
22	23.	Shi L, Liu J, Zhang Y, Chen M, Liu J, Shi L. β1 adrenoceptor antibodies induce myocardial apoptosis via
23		inhibiting PGC-1α-related pathway. BMC Cardiovasc Disord BioMed Central; 2020;20.
24	24.	Du Y, Yan L, Wang J, Zhan W, Song K, Han X, Li X, Cao J, Liu H. β1-Adrenoceptor Autoantibodies from

The correlation between peripartum cardiomyopathy and autoantibodies against cardiovascular receptors.

1		DCM Patients Enhance the Proliferation of T Lymphocytes through the β 1-AR/cAMP/PKA and p38 MAPK
2		Pathways. <i>PLoS One</i> Public Library of Science; 2012;7:e52911.
3	25.	Abdelkrim MA, Leonetti D, Montaudon E, Chatagnon G, Gogny M, Desfontis JC, Noireaud J, Mallem MY.
4		Antibodies against the second extracellular loop of β 1- adrenergic receptors induce endothelial dysfunction
5		in conductance and resistance arteries of the Wistar rat. Int Immunopharmacol Int Immunopharmacol;
6		2014;19:308–316.
7	26.	Wang J, Li M, Ma X, Bai K, Wang L, Yan Z, Lv T, Zhao Z, Zhao R, Liu H. Autoantibodies against the β 3-
8		Adrenoceptor Protect from Cardiac Dysfunction in a Rat Model of Pressure Overload. PLoS One PLOS;
9		2013;8:78207.
10	27.	Bornholz B, Roggenbuck D, Jahns R, Boege F. Diagnostic and therapeutic aspects of β 1-adrenergic receptor
11		autoantibodies in human heart disease. Autoimmun. Rev. Autoimmun Rev; 2014. p. 954–962.
12	28.	Herda LR, Felix SB, Boege F. Drug-like actions of autoantibodies against receptors of the autonomous
13		nervous system and their impact on human heart function. Br. J. Pharmacol. Br J Pharmacol; 2012. p. 847-
14		857.
15	29.	Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev
16		Allergy Immunol Nature Publishing Group; 2012;42:102–111.
17	30.	Burbelo PD, Iadarola MJ, Keller JM, Warner BM. Autoantibodies Targeting Intracellular and Extracellular
18		Proteins in Autoimmunity. Front Immunol Frontiers Media S.A.; 2021;12:5.
19	31.	Ludwig RJ, Vanhoorelbeke K, Leypoldt F, Kaya Z, Bieber K, McLachlan SM, Komorowski L, Luo J,
20		Cabral-Marques O, Hammers CM, Lindstrom JM, Lamprecht P, Fischer A, Riemekasten G, Tersteeg C,
21		Sondermann P, Rapoport B, Wandinger KP, Probst C, Beidaq A El, Schmidt E, Verkman A, Manz RA,
22	<i>y</i>	Nimmerjahn F. Mechanisms of autoantibody-induced pathology. Front Immunol Frontiers Media S.A.;
23		2017; 8 :603.
24	32.	Haller-Kikkatalo K, Alnek K, Metspalu A, Mihailov E, Metsküla K, Kisand K, Pisarev H, Salumets A, Uibo

1		R. Demographic associations for autoantibodies in disease-free individuals of a European population. Sci
2		Rep Nature Publishing Group; 2017;7.
3	33.	Akmatov MK, Röber N, Ahrens W, Flesch-Janys D, Fricke J, Greiser H, Günther K, Kaaks R, Kemmling Y,
4		Krone B, Linseisen J, Meisinger C, Moebus S, Obi N, Guzman CA, Conrad K, Pessler F. Anti-nuclear
5		autoantibodies in the general German population: Prevalence and lack of association with selected
6		cardiovascular and metabolic disorders-findings of a multicenter population-based study. Arthritis Res Ther
7		BioMed Central Ltd.; 2017; 19 :1–9.
8	34.	Mannoor K, Xu Y, Chen C. Natural autoantibodies and associated B cells in immunity and autoimmunity.
9		Autoimmunity Taylor & Francis; 2013;46:138–147.
10	35.	Hess C, Winkler A, Lorenz AK, Holecska V, Blanchard V, Eiglmeier S, Schoen AL, Bitterling J, Stoehr AD,
11		Petzold D, Schommartz T, Mertes MMM, Schoen CT, Tiburzy B, Herrmann A, Köhl J, Manz RA, Madaio
12		MP, Berger M, Wardemann H, Ehlers M. T cell-independent B cell activation induces immunosuppressive
13		sialylated IgG antibodies. J Clin Invest J Clin Invest; 2013;123:3788–3796.
14	36.	Du Y, Li X, Yu H, Yan L, Lau WB, Zhang S, Qin Y, Wang W, Ma X, Liu H, Fu M. Activation of T
15		Lymphocytes as a Novel Mechanism in Beta1-Adrenergic Receptor Autoantibody-Induced Cardiac
16		Remodeling. Cardiovasc Drugs Ther Springer New York LLC; 2019;33:149–161.
17	37.	Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, Devalaraja M, Anker SD, Cleland JG, Dickstein K,
18		Filippatos GS, Harst P van der, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, Zannad F,
19		Zwinderman AH, Hillege HL, Veldhuisen DJ van, Kakkar R, Voors AA, Meer P van der. The clinical
20		significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Fail Eur J
21		Heart Fail; 2019; 21 :965–973.
22	Y	

- 23
- 24

1 Figure legends

Figure 1. A. Directed acyclic graph displaying the 13 over-represented GO biological processes containing
the terms "B cell" and "immunoglobulin". Non-redundant children terms selected for further analysis are
highlighted in blue. A higher resolution version of this image is presented in Supplementary Figure 2. B.
Detailed results of pathway over-representation analysis for the 13 selected biological processes, including
the p-value, intersection size and term size. C. Network denoting biomarker membership to the 5 GO
biological processes that were used for further analyses. GO gene ontology; ID identifier; HGNC HUGO
Gene Nomenclature Committee.

9

Figure 2. A. Half-violin plots and boxplots with individual data points of assay binding indices for all investigated autoantibodies, presented separately for healthy controls and patients with HF. B. Relative prevalence of seronegative, intermediate and seropositive status for each autoantibody in healthy controls and patients with HF. C. Venn diagram illustrating the co-occurrence of intermediate and/or seropositive status for each autoantibody in patients with HF. D. Venn diagram illustrating overlapping seropositivity

15 for each autoantibody in patients with HF. HF heart failure

16

Figure 3. Kaplan-Meier curves for the combined outcome (all-cause mortality and rehospitalization for HF) censored at 2 years (**row A**), and for all-cause mortality alone (**row B**), as well as cumulative incidence function curves for rehospitalization for HF only with all-cause mortality as a competing risk (**row C**). From left to right, results of univariable analyses for anti- β 1, anti- β 2, anti- β 3, and anti-M2 autoantibodies. HF

21 heart failure

22

Figure 4. Sensitivity analyses of the results presented in Figure 3, by stratifying categories as seronegative/intermediate and seropositive. Kaplan-Meier curves for the combined outcome (all-cause mortality and rehospitalization for HF) censored at 2 years (row A), and for all-cause mortality alone (row B), as well as cumulative incidence function curves for rehospitalization for HF only with all-cause mortality as a competing risk (row C). For anti- β 1 autoantibodies, Cox regression analyses for the combined outcome and competing risks analyses for HF-related rehospitalization (both univariable and multivariable) are presented in the results section. HF heart failure

30

Figure 5. Biplot of principal component analysis of the 31 biomarkers involved in B-lymphocyte-associated biological processes. The intermediate group for each AAB was excluded to accentuate potential differences. Considerable overlap is seen between groups in all comparisons. For optimal visualization, only the top fifteen biomarkers that contributed the most to the first principal component are shown. The relative contribution of all examined biomarkers is shown in **Supplementary Figure 3**). AAB autoantibody

1 Table 1. Baseline characterist	ics for the entire patient co	phort and stratified accord	ina to anti-61-adreneraic re	eceptor autoantibody sta	Downloade tus. e
Variable	Whole Cohort	Anti-β1 Seronegative	Anti-β1 Intermediate	Anti-B1 Seropositive	p-value
Group Size	2256	1399	743	114	N/A T
Demographics					1
Age (Years)	69 (12)	69 (12)	69 (11)	70 (12)	0.568 ^{ff} ₀
Female sex	602 (26.7%)	401 (28.7%)	167 (22.5%)	34 (29.8%)	0.006*
Recruited as outpatient	822 (32.6%)	455 (32.6%)	242 (32.6%)	37 (32.5%)	0.999 🖁
Primary HF Etiology					Ide
Cardiomyopathy	556 (25.1%)	372 (27.1%)	169 (23.2%)	15 (13.4%)	0.002*
Hypertensive	233 (10.5%)	137 (10.0%)	85 (11.7%)	11 (9.8%)	0.468 0
Ischemic	1018 (46.0%)	619 (45.1%)	342 (47.0%)	57 (50.9%)	0.402 년
Valvular Disease	167 (7.5%)	104 (7.6%)	49 (6.7%)	14 (12.5%)	0.099 8
Previous History and					m/c
Comorbidities					car
AF	1024 (45.4%)	636 (45.5%)	331 (44.5%)	57 (50.0%)	0.549 0
DM	732 (32.5%)	459 (32.9%)	237 (31.9%)	36 (31.6%)	0.884 ឆ្ល
HT	1398 (62.0%)	868 (62.1%)	458 (61.6%)	72 (63.2%)	0.944 ^o
RD	628 (27.9%)	366 (26.2%)	216 (29.1%)	46 (40.4%)	0.004* 🖉
Anemia	746 (36.4%)	446 (35.1%)	250 (37.0%)	50 (47.2%)	0.043*
COPD	395 (17.5%)	232 (16.6%)	133 (17.9%)	30 (26.3%)	0.030 *≦
MI	864 (38.3%)	525 (37.6%)	297 (40.0%)	42 (36.8%)	0.525
Stroke	212 (9.4%)	133 (9.5%)	70 (9.4%)	9 (7.9%)	0.849 💩
HF Hospitalization during	711 (31.5%)	439 (31.4%)	242 (32.6%)	30 (26.3%)	0.404
previous year	. ,				le/
Smoking					0.404 (doi/10.1093/cvr/cvad042/7072338 0.226 0.226 0.295 0.095
Never	824 (36.6%)	534 (38.3%)	252 (34.0%)	38 (33.6%)	/10
Past	1105 (49.1%)	656 (47.0%)	390 (52.6%)	59 (52.2%)	0.16
Current	322 (14.3%)	206 (14.8%)	100 (13.5%)	16 (14.2%))93
Clinical Characteristics					/cv
NYHA Functional Class					'r/c
L. L.	209 (10.6%)	132 (10.9%)	66 (10.1%)	11 (10.8%)	Va
II	1014 (51.6%)	644 (53.2%)	323 (49.6%)	47 (46.1%)	0.226
	663 (33.8%)	391 (32.3%)	236 (36.3%)	36 (35.3%)	12/
IV	78 (4.0%)	44 (3.6%)	26 (4.0%)	8 (7.8%)	6
					23
NYHA Class III or IV	741 (37.7%)	435 (35.9%)	262 (40.2%)	44 (43.1%)	0.095
BMI (kg/m²)	27.1 [24.1, 30.5]	27.2 [24.2, 30.8]	27.2 [24.0, 30.5]	25.9 [23.6, 29.1]	0.089 👳
HR (beats/min)	76 [67, 90]	76 [67, 88]	76 [67, 90]	75 [67, 85]	0.813 0
SBP (mm Hg)	125 (22)	125 (22)	125 (23)	126 (21)	0.907 🗄
DBP (mm Hg)	75 (13)	75 (13)	75 (14)	73 (14)	0.179 Z
Pulmonary Crackles	1156 (52.8%)	716 (52.7%)	381 (53.1%)	59 (53.2%)	0.984 🎽
6MWT Successfully Completed	1413 (64.8%)	888 (65.7%)	459 (64.2%)	66 (58.4%)	0.266 🍳
6MWT Distance (m)	220 [0, 350]	222 [0, 356]	216 [0, 350]	160 [0, 328]	0.685 _
LVEF (%)	30 [25, 36]	30 [25, 35]	30 [25, 37]	33 [25, 40]	0.052 🗑
LVEF > 40%	216 (10.7%)	122 (9.8%)	77 (11.7%)	17 (16.7%)	0.062
Laboratory Indices					5
NT-proBNP (pg/mL)	2721.0 [1204.3, 5741.8]	2608.5 [1204.3, 5337.5]	2798.0 [1170.0, 6460.0]	3144.0 [1513.0, 6073.0]	0.289 🖸
CRP (mg/L)	13.0 [5.8, 26.4]	12.5 [5.8, 26.4]	13.5 [5.8, 26.6]	15.1 [4.8, 26.6]	0.711 ^{\]}
eGFR (mL/min/1.73 m ²)	65.0 (26.2)	65.5 (25.7)	64.8 (26.6)	60.1 (29.2)	0.108
Creatinine (µmol/L)	101.0 [82.1, 128.2]	100.0 [81.0, 125.0]	102.0 [84.0, 132.6]	106.1 [88.1, 151.5]	0.027* _N
Hb (g/dL)	13.2 (1.9)	13.2 (1.9)	13.2 (1.9)	12.8 (1.9) †	0.047*

Medications					
BB	1880 (83.4%)	1159 (83.0%)	624 (84.0%)	97 (85.1%)	0.737
BB at target dose	127 (5.6%)	74 (5.3%)	43 (5.8%)	10 (8.8%)	0.295
BB Fraction of Target Dose	0.25 [0.06, 0.50]	0.25 [0.06, 0.48]	0.25 [0.06, 0.50]	0.25 [0.06, 0.50]	0.527
ACEi/ARB	1615 (71.7%)	1011 (72.4%)	531 (71.5%)	73 (64.0%)	0.163 🞖
ACEi/ARB at target dose	295 (13.1%)	181 (13.0%)	99 (13.3%)	15 (13.2%)	0.971 🛓
ACEi/ARB Fraction of Target Dose	0.25 [0.00, 0.50]	0.25 [0.00, 0.50]	0.25 [0.00, 0.50]	0.25 [0.00, 0.50]	0.267
MRA	1196 (53.1%)	766 (54.8%)	379 (51.0%)	51 (44.7%)	0.045*
Digoxin	424 (18.8%)	259 (18.5%)	149 (20.1%)	16 (14.0%)	0.283 🚊
Oral hypoglycemic agents**	457 (62.4%)	290 (63.2%)	150 (63.3%)	17 (47.2%)	0.155 9

Table 2. Baseline characteristics strati	fied according to anti-B2	-adreneraic recentor autoantihodu s	tatus
TUDIE 2. DUSEITTE CHUTUCLETISTICS STIUT	11EU ULLUI UIII IU UIILI-02	-uurenergic receptor uutountibouy s	iuius.

	atriuretic Peptide; CI MRA mineralocortico	RP C-reactive protein; Hb hemo			ntricular eject
ensin receptor blocker; post-hoc testing.	MRA mineralocortico	-	globin; BB β-adrenoreceptor ant	agonist; ACEi angiotensin coi	nverting enzy
post-hoc testing.		oid receptor antagonist. *p≤0.0	5; **only for patients with diabe	tes mellitus; +significantly di	fferent from s
Tahle 2 Baseline	characteristics st	ratified according to anti-	82-adreneraic recentor aut	oantihody status	
Varia	ble	Anti-B2 Seronegative	Anti-62 Intermediate	Anti-B2 Seropositive	p-value
Group Size	JIC .	1326	797	133	N/A
Demographics		1920		100	
DemoBraphies	Age (Years)	69 (12) †	68 (13)	69 (12)	0.046*
	Female sex	373 (28,2%)	190 (23.9%)	39 (29.3%)	0.076
Recr	uited as outpatient	458 (34.6%)	223 (28.0%)	53 (39.8%)	0.001*
Primary HF Etiology					
,01	Cardiomyopathy	325 (24.9%)	197 (25.3%)	34 (26.0%)	0.96
	Hypertensive	132 (10.1%)	80 (10.3%)	21 (16.0%)	0.106
	Ischemic	606 (46.5%)	359 (46.1%)	53 (40.5%)	0.415
	Valvular Disease	96 (7.4%)	62 (8.0%)	9 (6.9%)	0.846
Previous History and	Comorbidities				
	AF	608 (45.9%)	355 (44.6%)	61 (45.9%)	0.842
	DM	451 (34.0%)	242 (30.4%)	39 (29.3%)	0.162
	HT	828 (62.5%)	485 (60.9%)	85 (63.9%)	0.695
	RD	375 (28.3%)	218 (27.4%)	35 (26.3%)	0.829
	Anemia	438 (36.4%)	269 (36.8%)	39 (32.8%)	0.691
	COPD	235 (17.7%)	130 (16.3%)	30 (22.6%)	0.207
	MI	525 (39.6%)	299 (37.6%)	40 (30.1%)	0.083
	Stroke	129 (9.7%)	63 (7.9%)	20 (15.0%)	0.027*
HF Hospitalization d	uring previous year	419 (31.6%)	252 (31.7%)	40 (30.1%)	0.932
Smoking	Navor	404 (27 49/)	284 (25 70/)	AC (24 CO/)	
	Dest	494 (37.4%)	284 (35.7%)	40 (34.0%) 60 (45.1%)	0.021*
	Current	163 (12 3%)	132 (16.6%)	27 (20 3%)	0.021
Clinical Characteristic	cunelit	103 (12.370)	132 (10.0%)	27 (20.370)	
NYI	A Functional Class				
		121 (10.5%)	79 (11.4%)	9 (7.8%)	
	i i	602 (52.2%)	348 (50.1%)	64 (55.7%)	0.32
		377 (32.7%)	246 (35.4%)	40 (34.8%)	
	IV	54 (4.7%)	22 (3.2%)	2 (1.7%)	
	NYHA Class III or IV	431 (37.3%)	268 (38.6%)	42 (36.5%)	0.841
	BMI (kg/m ²)	27.2 [24.2, 30.9]	27.1 [24.2, 30.4]	26.6 [23.5, 29.5]	0.104
	HR (beats/min)	76 [66, 89]	77 [68, 90]	75 [65, 87]	0.158
	SBP (IIIIII Hg)	125 (22)	124 (22)	127 (23)	0.221
	DBP (mm Hg)	75 (13)	75 (13)	75 (14)	0.95
	Pulmonary Crackles	669 (52.2%)	417 (53.6%)	70 (54.3%)	0.787
	essfully Completed	837 (65.5%)	501 (64.9%)	75 (57.7%)	0.203
e	MWT Distance (m)	220 [0, 350]	224 [0, 356]	161 [0, 326]	0.237
	LVEF (%)	30 [25, 37]	30 [24, 35]	30 [25, 35]	0.036*
	LVEF > 40%	145 (12.2%)	60 (8.5%)	11 (9.2%)	0.034*

Laboratory Indices				
NT-proBNP (pg/mL)	2798.0 [1226.5, 5738.0]	2678.5 [1200.5, 5803.5]	2542.0 [905.5, 5606.0]	0.885
CRP (mg/L)	13.4 [5.8, 26.7]	12.5 [5.9, 24.9]	11.9 [3.7, 26.6]	0.379
eGFR (mL/min/1.73 m ²)	64.2 (25.4)	66.0 (27.3)	66.2 (28.0)	0.275
Creatinine (μmol/L)	101.7 [82.0, 128.0]	101.3 [83.1, 131.9]	96.8 [80.0, 118.8]	0.638
Hb (g/dL)	13.2 (1.9)	13.2 (1.9)	13.4 (1.8)	0.512
Medications				
BB	1107 (83.5%)	660 (82.9%)	113 (85.0%)	0.823
BB at target dose	79 (6.0%)	39 (4.9%)	9 (6.8%)	0.497
BB Fraction of Target Dose	0.25 [0.06, 0.50]	0.25 [0.06, 0.38]	0.25 [0.08, 0.38]	0.617
ACEi/ARB	941 (71.0%)	569 (71.5%)	105 (78.9%)	0.153
ACEi/ARB at target dose	170 (12.8%)	106 (13.3%)	19 (14.3%)	0.869
ACEi/ARB Fraction of Target Dose	0.25 [0.00, 0.50]	0.25 [0.00, 0.50]	0.25 [0.12, 0.50]	0.099
MRA	677 (51.1%)	458 (57.5%)	61 (45.9%)	0.004*
Digoxin	252 (19.0%)	149 (18.7%)	23 (17.3%)	0.886
Oral hypoglycemic agents**	272 (60.3%)	165 (68.2%)	20 (51.3%)	0.042*

HF heart failure; AF atrial fibrillation; DM diabetes mellitus; HT hypertension; RD renal disease; COPD chronic obstructive pulmonary disease; MI myocardial infarction; NYHA New York heart association; BMI body mass index; HR heart rate; SBP/DBP; systolic/diastolic blood pressure; 6MWT 6-minute walk test; LVEF left ventricular ejection fraction; NT-proBNP N-Terminal pro-Brain Natriuretic Peptide; CRP C-reactive protein; Hb hemoglobin; BB β-adrenoreceptor antagonist; ACEi angiotensin converting enzyme inhibitor; ARB angiotensin receptor blocker; MRA mineralocorticoid receptor antagonist. *p≤0.05; **only for patients with diabetes mellitus; †significantly different from intermediate patients in post-hoc testing.

Table 3. Baseline characteristics stratified according to anti-63-adrenergic receptor autoantibody status.

Variable	Anti-β3 Seronegative	Anti-β3 Intermediate	Anti-β3 Seropositive	p-valu
Group Size	1575	640	41	N/A
Demographics				
Age (Years)	69 (12)	69 (12)	71 (11)	0.346
Female sex	430 (27.3%)	160 (25.0%)	12 (29.3%)	0.495
Recruited as outpatient	504 (32.0%)	213 (33.3%)	17 (41.5%)	0.402
Primary HF Etiology				
Cardiomyopathy	393 (25.5%)	156 (24.6%)	7 (17.9%)	0.532
Hypertensive	154 (10.0%)	76 (12.0%)	3 (7.7%)	0.322
Ischemic	716 (46.5%)	284 (44.9%)	18 (46.2%)	0.794
Valvular Disease	113 (7.3%)	50 (7.9%)	4 (10.3%)	0.732
Previous History and Comorbidities				
AF	687 (43.7%)	316 (49.4%)	21 (51.2%)	0.038
DM	516 (32.8%)	202 (31.6%)	14 (34.1%)	0.83
НТ	988 (62.8%)	385 (60.2%)	25 (61.0%)	0.502
RD	419 (26.6%)	196 (30.6%)	13 (31.7%)	0.142
Anemia	513 (35.5%)	222 (38.9%)	11 (29.7%)	0.248
COPD	260 (16.5%)	123 (19.2%)	12 (29.3%)	0.044
MI	611 (38.8%)	241 (37.7%)	12 (29.3%)	0.423
Stroke	151 (9.6%)	55 (8.6%)	6 (14.6%)	0.391
HF Hospitalization during previous year	482 (30.6%)	215 (33.6%)	14 (34.1%)	0.374
Smoking				
Never	575 (36.6%)	236 (37.0%)	13 (31.7%)	
Past	765 (48.7%)	321 (50.3%)	19 (46.3%)	0.453
Current	232 (14.8%)	81 (12.7%)	9 (22.0%)	

Clinical Characteristics				
NYHA Functional Class				
	142 (10.4%)	64 (11.3%)	3 (8.3%)	
	717 (52.6%)	276 (48.9%)	21 (58.3%)	0.599
	448 (32.8%)	205 (36.3%)	10 (27.8%)	0.555
IV	57 (4.2%)	19 (3.4%)	2 (5.6%)	
10	57 (4.270)	15 (5.470)	2 (5.676)	b
NYHA Class III or IV	505 (37.0%)	224 (39.7%)	12 (33.3%)	0.465
BMI (kg/m ²)	27.2 [24.2, 30.8]	26.9 [23.8, 30.2]	26.6 [24.2, 29.1]	0.224
HR (beats/min)	76 [67, 89]	76 [67, 90]	72 [63, 87]	0.494
SBP (mm Hg)	125 (22)	124 (22)	123 (19)	0.609
DBP (mm Hg)	75 (13)	75 (13)	73 (11)	0.432
Pulmonary Crackles	789 (51.5%)	344 (55.8%)	23 (56.1%)	0.178
6MWT Successfully Completed	997 (65.4%)	394 (64.1%)	22 (56.4%)	0.456
6MWT Distance (m)	225 [0, 360]	215 [0, 344]	197 [0, 314]	0.39
LVEF (%)	30 [25, 36]	30 [24, 36]	30 [25, 35]	0.553
LVEF > 40%	147 (10.5%)	64 (11.2%)	5 (13.9%)	0.737
Laboratory Indices				
NT-proBNP (pg/mL)	2600.0 [1158.0, 5581.0]	2950.0 [1296.5, 5995.5]	2685.5 [1356.5, 5958.8]	0.153
CRP (mg/L)	12.8 [5.7, 26.2]	13.2 [6.0, 26.8]	19.2 [6.9, 32.6]	0.23
eGFR (mL/min/1.73 m ²) †	65.9 (26.6)	63.0 (24.9)	60.5 (31.3)	0.032*
Creatinine (µmol/L)	100.0 [80.9, 126.0]	102.8 [86.0, 133.0]	112.0 [84.0, 140.6]	0.027*
Hb (g/dL)	13.2 (1.9)	13.1 (2.0)	13.4 (1.8)	0.401
Medications				
BB	1307 (83.1%)	538 (84.1%)	35 (85.4%)	0.808
BB at target dose	84 (5.3%)	36 (5.6%)	7 (17.1%)	0.006*
BB Fraction of Target Dose	0.25 [0.06, 0.48]	0.25 [0.08, 0.50]	0.25 [0.05, 0.50]	0.351
ACEi/ARB	1137 (72.3%)	446 (69.7%)	32 (78.0%)	0.309
ACEi/ARB at target dose	201 (12.8%)	87 (13.6%)	7 (17.1%)	0.654
ACEi/ARB Fraction of Target Dose	0.25 [0.00, 0.50]	0.25 [0.00, 0.50]	0.25 [0.12, 0.50]	0.324
MRA	835 (53.1%)	339 (53.0%)	22 (53.7%)	0.996
Digoxin	293 (18.6%)	122 (19.1%)	9 (22.0%)	0.85
Oral hypoglycemic agents**	322 (62.4%)	127 (62.9%)	8 (57.1%)	0.912

HF heart failure; AF atrial fibrillation; DM diabetes mellitus; HT hypertension; RD renal disease; COPD chronic obstructive pulmonary disease; MI myocardial infarction; NYHA New York heart association; BMI body mass index; HR heart rate; SBP/DBP; systolic/diastolic blood pressure; 6MWT 6-minute walk test; LVEF left ventricular ejection fraction; NT-proBNP N-Terminal pro-Brain Natriuretic Peptide; CRP C-reactive protein; Hb hemoglobin; BB β-adrenoreceptor antagonist; ACEi angiotensin converting enzyme inhibitor; ARB angiotensin receptor blocker; MRA mineralocorticoid receptor antagonist. *p<0.05; **only for patients with diabetes mellitus; †no significant between-group differences in post-hoc testing.


1


 Table 4. Baseline characteristics stratified according to anti-M2-muscarinic receptor autoantibody status.


	Variable	Anti-M2 Seronegative	Anti-M2 Intermediate	Anti-M2 Seropositive	p-value
Group Size		1213	871	172	N/A
Demographics					
	Age (Years)	69 (12)	69 (13)	70 (11)	0.260
	Female sex	338 (27.9%)	215 (24.7%)	49 (28.5%)	0.224
	Recruited as outpatient	403 (33.1%)	276 (32.0%)	55 (32.0%)	0.862
Primary HF Eti	ology				
	Cardiomyopathy	301 (25.3%)	214 (25.1%)	41 (24.0%)	0.935
	Hypertensive	116 (9.7%)	102 (12.0%)	15 (8.8%)	0.195
	Ischemic	539 (45.3%)	399 (46.9%)	80 (46.8%)	0.750
	Valvular Disease	87 (7.3%)	66 (7.8%)	14 (8.2%)	0.881


Previous History and Comorbidities				
AF	540 (44.6%)	400 (45.9%)	84 (48.8%)	0.539
DM	376 (31.0%)	296 (34.0%)	60 (34.9%)	0.289
HT	733 (60.5%)	555 (63.7%)	110 (64.0%)	0.289
RD	329 (27.2%)	255 (29.3%)	44 (25.6%)	0.449
Anemia	409 (36.9%)	286 (36.1%)	51 (33.6%)	0.704
COPD	204 (16.8%)	152 (17.5%)	39 (22.7%)	0.170
MI	454 (37.5%)	345 (39.6%)	65 (37.8%)	0.611
Stroke	122 (10.1%)	79 (9.1%)	11 (6.4%)	0.275
HF Hospitalization during previous year	383 (31.4%)	276 (32.0%)	52 (30.2%)	0.895
Smoking				
Never	436 (36.0%)	332 (38.2%)	56 (32.6%)	
Past	606 (50.1%)	405 (46.6%)	94 (54.7%)	0.308
Current	168 (13.9%)	132 (15.2%)	22 (12.8%)	
Clinical Characteristics				
NYHA Functional Class				
1	109 (10.4%)	84 (11.0%)	16 (10.5%)	
II	561 (53.4%)	370 (48.6%)	83 (54.2%)	0.518
	339 (32.3%)	277 (36.4%)	47 (30.7%)	
IV	41 (3.9%)	30 (3.9%)	7 (4.6%)	
NYHA Class III or IV	380 (36.2%)	307 (40.3%)	54 (35.3%)	0.161
BMI (kg/m ²)	27.0 [24.0, 30.5]	27.2 [24.2, 30.8]	27.3 [24.5, 30.5]	0.382
HR (beats/min)	76 [66, 90]	76 [67, 90]	75 [69, 88]	0.898
SBP (mm Hg)	125 (23)	124 (21)	123 (20)	0.131
DBP (mm Hg)	75 (14)	75 (13)	74 (12.2)	0.407
Pulmonary Crackles	615 (52.3%)	454 (54.0%)	87 (50.6%)	0.634
6MWT Successfully Completed	765 (65.3%)	552 (65.6%)	96 (57.8%)	0.142
6MWT Distance (m)	230 [0, 350]	217 [0, 350]	167 [0, 360]	0.539
LVEF (%)	30 [25, 37]	30 [25, 36]	30 [25, 35]	0.832
LVEF > 40%	119 (11.1%)	82 (10.6%)	15 (9.3%)	0.775
Laboratory Indices				
NT-proBNP (pg/mL)	2711.0 [1157.5, 5460.0]	2879.0 [1268.0, 6066.0]	2356.0 [1231.8, 5396.8]	0.253
CRP (mg/L)	13.1 [5.7, 25.0]	13.0 [5.9, 27.1]	13.2 [5.5, 27.1]	0.847
eGFR (mL/min/1.73 m ²)	65.4 (25.8)	64.4 (26.8)	65.0 (26.3)	0.664
Creatinine (µmol/L)	100.0 [82.0, 126.4]	104.2 [83.0, 132.6]	99.5 [83.7, 132.2]	0.167
Hb (g/dL)	13.2 (1.9)	13.2 (1.9)	13.3 (2.0)	0.826
Medications	1020 (04 20/)	715 (02 10/)	145 (04 20()	0.410
BB	1020 (84.2%)	715 (82.1%)	145 (84.3%)	0.410
BB at target dose	69 (5.7%)	45 (5.2%)		0.457
BB Fraction of Target Dose ACEi/ARB	0.25 [0.06, 0.50]	0.24 [0.06, 0.48]	0.25 [0.06, 0.50]	0.347
ACEI/ARB ACEI/ARB at target dose	866 (71.5%)	625 (71.8%) 105 (12.1%)	124 (72.1%)	0.984 0.040*
ACEI/ARB at target dose ACEI/ARB Fraction of Target Dose		· · ·	33 (19.2%) 0.25 [0.00, 0.50]	0.040* 0.956
ACEI/ARB Fraction of Target Dose MRA	0.25 [0.00, 0.50]	0.25 [0.00, 0.50]	104 (60.5%)	0.956 0.026*
Digoxin	615 (50.8%) 222 (18.4%)	477 (54.8%) 169 (19.4%)	104 (60.5%) 32 (18.6%)	0.848
Oral hypoglycemic agents**	223 (18.4%) 227 (60.4%)	191 (64.5%)	32 (18.6%)	0.848
Ural hypoglycemic agents**		191 (64.5%)	39 (65.0%)	0.496


HF heart failure; AF atrial fibrillation; DM diabetes mellitus; HT hypertension; RD renal disease; COPD chronic obstructive pulmonary disease; MI myocardial infarction; NYHA New York heart association; BMI body mass index; HR heart rate; SBP/DBP; systolic/diastolic blood pressure; 6MWT 6-minute walk test; LVEF left ventricular ejection fraction; NT-proBNP N-Terminal pro-Brain Natriuretic Peptide; CRP C-reactive protein; Hb hemoglobin; BB β-adrenoreceptor antagonist; ACEi angiotensin converting enzyme inhibitor; ARB angiotensin receptor blocker; MRA mineralocorticoid receptor antagonist. *p<0.05; **only for patients with diabetes mellitus.











Clinical and Prognostic Associations of Autoantibodies Recognizing Adrenergic/Muscarinic Receptors in Patients with Heart Failure

